Pharming Group NV
PHAR11.977USD
+1.017+9.28%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Pharming Group NV Unternehmen
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Unternehmensinformationen
BörsenkürzelPHAR
Name des UnternehmensPharming Group NV
IPO-datumJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
AddresseDarwinweg 24
StadtLEIDEN
BörseLondon Stock Exchange
LandNetherlands
Postleitzahl2333 CR
Telefon31715247400
Websitehttps://www.pharming.com/
BörsenkürzelPHAR
IPO-datumJul 02, 1998
CEODr. Sijmen (Sijmen) De Vries, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeroen Wakkerman
Mr. Jeroen Wakkerman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Stephen Toor
Mr. Stephen Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeroen Wakkerman
Mr. Jeroen Wakkerman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Fabrice Chouraqui
Mr. Fabrice Chouraqui
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Stephen Toor
Mr. Stephen Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Alexander Breidenbach
Dr. Alexander Breidenbach
Chief Business Officer
Chief Business Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, May 14
Aktualisiert: Wed, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Aktionäre
Aktionäre
Anteil
Silverberg Bernstein Capital Management, LLC
0.08%
Other
99.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
0.08%
Other
99.92%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
10
57.25K
0.08%
-7.99K
2025Q1
11
75.56K
0.11%
-12.14K
2024Q4
11
75.65K
0.11%
-65.36K
2024Q3
11
69.30K
0.10%
-54.56K
2024Q2
9
52.15K
0.08%
-64.69K
2024Q1
9
45.12K
0.07%
-72.64K
2023Q4
9
45.06K
0.07%
-55.56K
2023Q3
9
38.77K
0.06%
-67.63K
2023Q2
10
27.05K
0.04%
-248.66K
2023Q1
10
87.93K
0.13%
-131.45K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Silverberg Bernstein Capital Management, LLC
48.00K
0.07%
--
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
2.50K
0%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
2.09K
0%
--
--
May 31, 2025
Morgan Stanley & Co. LLC
400.00
0%
+300.00
+300.00%
Mar 31, 2025
Coldstream Capital Management, Inc.
106.00
0%
+106.00
--
Mar 31, 2025
Osaic Holdings, Inc.
--
0%
-483.00
-100.00%
Mar 31, 2025
Farther Finance Advisors, LLC
--
0%
-11.00
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
--
0%
-10.00
-100.00%
Mar 31, 2025
Orion Portfolio Solutions, LLC
--
0%
-11.71K
-100.00%
Dec 31, 2023
Aperio Group, LLC
--
0%
-326.00
-100.00%
Dec 31, 2024
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
